Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All Evaluable Lesions, Meeting The Primary Endpoint

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product